Topic: ai drug discovery
-
Google DeepMind Open-Sources TxGemma: Turbocharging Drug Discovery with AI
Google DeepMind has launched TxGemma, an open-source AI model suite designed to enhance the drug discovery and development process, addressing inefficiencies and high failure rates in clinical trials.
Read More » -
Converge Bio Secures $25M From Bessemer, Meta, OpenAI, Wiz Execs
Converge Bio, a startup specializing in AI for drug discovery, secured $25 million in Series A funding led by Bessemer Venture Partners, with backing from major tech executives. The company uses generative AI trained on molecular data to provide integrated systems for the entire drug development ...
Read More » -
Chai Discovery Raises $130M Series B at $1.3B Valuation
Chai Discovery secured $130 million in Series B funding, reaching a $1.3 billion valuation, with investment led by top venture capital firms. The company develops AI foundation models to predict molecular interactions and accelerate drug discovery, notably in *de novo* antibody design. Its latest...
Read More » -
DeepMind CEO: AI Slashes Drug Discovery Time, Revolutionizing Medicine
AI is set to dramatically shorten drug development timelines, potentially reducing the process from over a decade to just months by accelerating the identification and testing of new treatments. AI-driven predictive modeling minimizes failures in drug development by forecasting molecular interact...
Read More » -
AI-Powered Hunt for Antibiotics in Unexpected Places
AI is revolutionizing antibiotic discovery by analyzing vast genetic data to identify novel antimicrobial compounds, addressing the critical challenge of antimicrobial resistance. Researchers like César de la Fuente are using AI to find antibiotic peptides in diverse sources, including ancient or...
Read More » -
AI's Role in Solving Rare Disease Treatment Shortages
Artificial intelligence is transforming drug discovery by enabling small teams to tackle previously neglected diseases, acting as a productivity multiplier to overcome talent shortages and resource constraints. AI is being applied to both drug design and targeted gene therapy delivery, with compa...
Read More » -
Antiverse Secures $9.3M to Scale AI-Powered Antibody Discovery
Antiverse, a Cardiff-based biotech firm, has secured a $9.3 million Series A investment to scale its AI-driven drug discovery platform and advance internal therapeutic programs. The company specializes in using machine learning to design therapeutic antibodies for challenging protein targets, suc...
Read More » -
Build a Bold AI Startup: Embrace Risk, Defy Norms
The AI startup landscape is intensely crowded and competitive, with thousands of new companies emerging and securing significant funding, yet facing brutal challenges from tech giants and market saturation. Bindwell, founded by teenagers like Navvye Anand, exemplifies how AI is accelerating innov...
Read More » -
Demis Hassabis and the New Logic of Discovery
The Nobel Prize in Chemistry doesn't usually go to computer scientists. But Demis Hassabis, the mind behind Google DeepMind, just won one. His AI, AlphaFold, solved the 50-year-old protein folding problem, creating a new atlas for biology and drug discovery.
Read More »